Alnylam Pharmaceuticals, Inc. (ALNY)

Last Closing Price: 465.34 (2025-12-04)

Net Income (Quarterly)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Alnylam Pharmaceuticals, Inc. (ALNY) had Net Income of $251.08M for the most recently reported fiscal quarter, ending 2025-09-30.

Figures for fiscal quarter ending 2025-09-30
Income Statement Financials
$1.25B
Net Income
$251.08M
$200.15M
$1.05B
$881.04M
$367.98M
$-129.01M
$238.97M
$238.97M
$251.08M
$251.08M
$251.08M
$251.08M
$367.98M
$381.79M
131.45M
137.35M
$1.91
$1.84
Balance Sheet Financials
$3.95B
$501.75M
$898.85M
$4.85B
$1.56B
$1.04B
$3.06B
$4.62B
$233.89M
$233.89M
$233.89M
131.79M
Cash Flow Statement Financials
$360.52M
$473.50M
$-350.51M
$968.65M
$1.49B
$524.15M
$276.60M
--
--
Fundamental Metrics & Ratios
2.54
--
--
0.82
4.45
83.98%
29.46%
29.46%
--
19.13%
20.10%
$325.12M
--
--
--
0.26
2.66
1.29
69.52
107.35%
107.35%
5.18%
19.71%
$1.77
$2.37
$2.62